These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

923 related articles for article (PubMed ID: 27216430)

  • 1. The Role of STAT Signaling Pathways in the Pathogenesis of Systemic Lupus Erythematosus.
    Goropevšek A; Holcar M; Avčin T
    Clin Rev Allergy Immunol; 2017 Apr; 52(2):164-181. PubMed ID: 27216430
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pathogenic and Therapeutic Relevance of JAK/STAT Signaling in Systemic Lupus Erythematosus: Integration of Distinct Inflammatory Pathways and the Prospect of Their Inhibition with an Oral Agent.
    Alunno A; Padjen I; Fanouriakis A; Boumpas DT
    Cells; 2019 Aug; 8(8):. PubMed ID: 31443172
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Elevated STAT1 expression but not phosphorylation in lupus B cells correlates with disease activity and increased plasmablast susceptibility.
    Aue A; Szelinski F; Weißenberg SY; Wiedemann A; Rose T; Lino AC; Dörner T
    Rheumatology (Oxford); 2020 Nov; 59(11):3435-3442. PubMed ID: 32357246
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multidimensional single cell based STAT phosphorylation profiling identifies a novel biosignature for evaluation of systemic lupus erythematosus activity.
    Huang X; Guo Y; Bao C; Shen N
    PLoS One; 2011; 6(7):e21671. PubMed ID: 21799742
    [TBL] [Abstract][Full Text] [Related]  

  • 5. JAK-STAT signaling mediates the senescence of bone marrow-mesenchymal stem cells from systemic lupus erythematosus patients.
    Ji J; Wu Y; Meng Y; Zhang L; Feng G; Xia Y; Xue W; Zhao S; Gu Z; Shao X
    Acta Biochim Biophys Sin (Shanghai); 2017 Mar; 49(3):208-215. PubMed ID: 28177455
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expansion of T follicular helper-T helper 1 like cells through epigenetic regulation by signal transducer and activator of transcription factors.
    Ma X; Nakayamada S; Kubo S; Sakata K; Yamagata K; Miyazaki Y; Yoshikawa M; Kitanaga Y; Zhang M; Tanaka Y
    Ann Rheum Dis; 2018 Sep; 77(9):1354-1361. PubMed ID: 29853448
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Signal transducer and activator of transcription 5 is implicated in disease activity in adult and juvenile onset systemic lupus erythematosus.
    Meshaal S; El Refai R; El Saie A; El Hawary R
    Clin Rheumatol; 2016 Jun; 35(6):1515-20. PubMed ID: 27041383
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Jakinibs in systemic lupus erythematosus: progress and prospects.
    Mok CC
    Expert Opin Investig Drugs; 2019 Jan; 28(1):85-92. PubMed ID: 30462559
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased Levels of STAT1 Protein in Blood CD4 T Cells from Systemic Lupus Erythematosus Patients Are Associated with Perturbed Homeostasis of Activated CD45RA
    Goropevšek A; Gorenjak M; Gradišnik S; Dai K; Holc I; Hojs R; Krajnc I; Pahor A; Avčin T
    J Interferon Cytokine Res; 2017 Jun; 37(6):254-268. PubMed ID: 28256939
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stage dependent aberrant regulation of cytokine-STAT signaling in murine systemic lupus erythematosus.
    Hale MB; Krutzik PO; Samra SS; Crane JM; Nolan GP
    PLoS One; 2009 Aug; 4(8):e6756. PubMed ID: 19707593
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Possible role of the JAK/STAT pathways in the regulation of T cell-interferon related genes in systemic lupus erythematosus.
    Kawasaki M; Fujishiro M; Yamaguchi A; Nozawa K; Kaneko H; Takasaki Y; Takamori K; Ogawa H; Sekigawa I
    Lupus; 2011 Oct; 20(12):1231-9. PubMed ID: 21980035
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Interleukin-2 signaling pathway regulating molecules in systemic lupus erythematosus].
    Guo Q; Chen XY; Su Y
    Beijing Da Xue Xue Bao Yi Xue Ban; 2016 Dec; 48(6):1100-1104. PubMed ID: 27987522
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multi-omics analysis uncovered systemic lupus erythematosus and COVID-19 crosstalk.
    Nian Z; Mao Y; Xu Z; Deng M; Xu Y; Xu H; Chen R; Xu Y; Huang N; Mao F; Xu C; Wang Y; Niu M; Chen A; Xue X; Zhang H; Guo G
    Mol Med; 2024 Jun; 30(1):81. PubMed ID: 38862942
    [TBL] [Abstract][Full Text] [Related]  

  • 14. JAK inhibitor has the amelioration effect in lupus-prone mice: the involvement of IFN signature gene downregulation.
    Ikeda K; Hayakawa K; Fujishiro M; Kawasaki M; Hirai T; Tsushima H; Miyashita T; Suzuki S; Morimoto S; Tamura N; Takamori K; Ogawa H; Sekigawa I
    BMC Immunol; 2017 Aug; 18(1):41. PubMed ID: 28830352
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Contribution and underlying mechanisms of CXCR4 overexpression in patients with systemic lupus erythematosus.
    Zhao LD; Liang D; Wu XN; Li Y; Niu JW; Zhou C; Wang L; Chen H; Zheng WJ; Fei YY; Tang FL; Li YZ; Zhang FC; He W; Cao XT; Zhang X
    Cell Mol Immunol; 2017 Oct; 14(10):842-849. PubMed ID: 27665947
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Th1/Th2/Th17/Treg cytokine imbalance in systemic lupus erythematosus (SLE) patients: Correlation with disease activity.
    Talaat RM; Mohamed SF; Bassyouni IH; Raouf AA
    Cytokine; 2015 Apr; 72(2):146-53. PubMed ID: 25647269
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Why Do We Need JAK Inhibitors in Systemic Lupus Erythematosus?
    Richter P; Cardoneanu A; Burlui AM; Macovei LA; Bratoiu I; Buliga-Finis ON; Rezus E
    Int J Mol Sci; 2022 Oct; 23(19):. PubMed ID: 36233087
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Abnormalities of the type I interferon signaling pathway in lupus autoimmunity.
    Gallucci S; Meka S; Gamero AM
    Cytokine; 2021 Oct; 146():155633. PubMed ID: 34340046
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Involvement of JAK/STAT signaling in the pathogenesis of inflammatory bowel disease.
    Coskun M; Salem M; Pedersen J; Nielsen OH
    Pharmacol Res; 2013 Oct; 76():1-8. PubMed ID: 23827161
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modifying T cell phenotypes using TYK2 inhibitor and its implications for the treatment of systemic lupus erythematosus.
    Satoh-Kanda Y; Nakayamada S; Kubo S; Yamagata K; Nawata A; Tanaka H; Kosaka S; Kanda R; Yu S; Fujita Y; Sonomoto K; Tanaka Y
    RMD Open; 2024 Jun; 10(2):. PubMed ID: 38871479
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 47.